The headline appears to refer to Roivant subsidiary Immunovant’s IMVT-1402, also called imeroprubart, an investigational FcRn-targeting autoimmune drug. However, the available results do not substantiate that it succeeded in two pivotal trials or that a 2027 filing is planned for it.
Roivant’s updates say potentially registrational IMVT-1402 trials in Graves’ disease and myasthenia gravis are expected to report topline results in 2027. That is a trial-readout timeline, not a confirmed filing date.
The search results also include reports of positive Phase 3 results for a different Roivant-linked drug, brepocitinib, in non-infectious uveitis, with a supplemental filing planned for the first half of 2027. The headline may be conflating these programs.
Separately, reports say IMVT-1402 failed a Phase 2b lupus study. So it would be misleading to summarize the headline as an across-the-board success for Roivant’s autoimmune drug pipeline.
Sources:
Roivant Reports Financial Results for the Fourth Quarter and Fiscal ...
Pfizer and Roivant launch autoimmune specialist Priovant
www.investing.com · news · transcriptsRoivant at Citi summit: cash-rich biotech leans on three ...
Immunovant's thyroid eye disease drug flunks pivotal trials
Roivant reports Phase 2b lupus failure for an FcRn drug
Roivant Sciences (ROIV) Earnings Call Transcripts
Roivant at Citi summit: cash-rich biotech leans on three pillars By Investing.com
Roivant at Citi summit: cash-rich biotech leans on three ...
Press Releases | Roivant Sciences Ltd.
Financial Results and Business Update for the Year Ended ...